Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 56-62

  Varterasian, Mary L ^a   Mohammad, Ramzi M ^a   Eilender, David S ^a   Hulburd, Kim ^a   Rodriguez, Dorothy H ^a   Pemberton, Pamela A ^a   Pluda, James M ^a   Dan, Maria D ^a   Pettit, George R ^a   Chen, Ben D ^a   Al Katib, Ayad M ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN 1; LACTONE DERIVATIVE; PROTEIN KINASE C;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; MYALGIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

EID: 0031982782     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.56     Document Type: Article

References (26)

1. Coltman CA, Dahlberg S, Jones SE, et al: CHOP is curative in thirty percent of patients with large cell lymphoma: A twelve year Southwest Oncology Group follow-up. Proc Am Soc Clin Oncol 5:197, 1986 (abstr)
2. Dana BW, Dahlberg S, Nathwani BN, et al: Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11:644-651, 1993
3. Pettit GR, Herald SL, Doubek DL, et al: Isolation and structure of bryostatin 1. J Am Chem Soc 104:6846-6848, 1982
4. Sharkis SJ, Jones RJ, Bellis ML, et al: The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood 76:716-720, 1990
5. Tuttle TM, Inge TH, Bethke KP, et al: Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res 52:548-553, 1992
6. Stone RM, Sariban E, Pettit GR, et al: Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood 72:208-213, 1988
7. Drexler HG, Gignac SM, Jones RA, et al: Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood 74:1747-1757, 1989
8. Stone RM, Sariban E, Pettit GR, et al: Bryostatin 1 activates protein kinase C and induces monocytic differentiation of B-chronic lymphocytic leukemia cells. Blood 74:1747-1757, 1989
9. Al-Katib A, Mohammad RM, Mohamed AN, et al: Conversion of a high grade lymphoma tumor cell line to intermediate grade with TPA and bryostatin as determined by polypeptide analysis on 2D-gel electrophoresis. Hematol Oncol 8:81-89, 1990
10. Hornung RL, Pearson JW, Beckwith M, et al: Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity. Cancer Res 52:101-107, 1992
11. Jones RJ, Sharkis SJ, Miller CB, et al: Bryostatin 1, a unique biological response modifier: antileukemic activity in vitro. Blood 75:1319-1323, 1990
12. Mohammad RM, Al-Katib A, Pettit GR, et al: Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 54:165-168, 1994
13. Kraft AS, Smith JB, Berkow RL: Bryostatin, an activator of calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic HL-60 cells. Proc Natl Acad Sci USA 83:1334-1338, 1986
14. Cheson BD, Bennett JM, Rai KR, et al: Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol 29:152-163, 1988
15. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
16. Al-Katib A, Mohammad RM, Khan K, et al: Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh. J Immunother 14:33-42, 1993
17. Philip PA, Rea D, Thavasu P, et al: Phase I study of Bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor α induction in vivo. J Natl Can Inst 85:1812-1818, 1993
18. Prendiville J, Crowther D, Thatcher N, et al: A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer 68:418-424, 1993
19. Jayson GC, Crowther D, Prendiville J, et al: A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. Br J Cancer 72:461-468, 1995
20. Mohammad RM, Al-Katib A, Pettit CR, et al: Differential effects of bryostatin 1 on human non-Hodgkin's B lymphoma cell lines. Leukemia Res 17:1-8, 1993
21. Al-Katib A, Mohammad RM. Differentiation of human B-cell tumors: A preclinical model for differentiation therapy, in Valeriote FA, Nakeff A, Valdivieso M (eds): Basic and Clinical Applications of Flow Cytometry. Norwell, MA, Kluwer Academic, 1996, pp 179-199
22. Mohammad RM, Al-Katib A, Pettit GR, et al: Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res 54:165-168, 1994
23. Mohammad RM, Diwakaran H, Maki A, et al: Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leukemia Res 19:667-673, 1995
24. Kamanda WS, Smith MR, Mohammad R, et al: Quantitative RT-PCR for mdr1, RNA in cell lines and in xenografts after bryostatin 1. Proc Am Assoc Can Res 35:545, 1994 (abstr 3248)
25. Maki A, Diwakaran H, Redman B, et al: The bcl-2 and p53 oncoproteins can be modulated by bryostatin 1 and dolastatins in human diffuse large cell lymphoma. Anticancer Drugs 6:392-397, 1995
26. Katato K, Mohammad RM, Dugan MC, et al: Sequential treatment of chronic lymphocytic leukemia (CLL) with bryostatin 1 and 2-chlorodeoxyadenosine: a preclinical study. Exp Hematol 24:1150, 1996 (abstr 693)